CAMBRIDGE, Mass. & OSAKA, Japan—Takeda Pharmaceutical Company Ltd. announced earlier this year that its Phase 3 ALTA-1L trial had met its primary endpoint in the first pre-specified interim analysis. ALUNBRIG treatment led to a statistically significant improvement in progression-free survival compared to crizotinib in adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who had not been previously treated with an ALK inhibitor. There were no new safety concerns associated with ALUNBRIG, as the drug candidate’s safety profile in the ALTA-1L trial proved generally consistent with established safety information.